In the quarter specifically, it’s important to note that HCA’s $4.027B adjusted EBITDA included a $543M Florida Medicaid directed-payment program (DPP) benefit. $423M of that benefit was related to pre-2026 periods. Deducting the full $423M pre-2026 benefit would reduce adjusted EBITDA to $3.604B, nearly 9% below pre-print FactSet consensus. This is a one-sided sensitivity, not a clean normalized comparison.

THC experienced similar patient migration from HIX to uninsured in its quarter. It also experienced similar inpatient surgery case softness and professional fee pressure, but was able to raise 2026 adjusted EBITDA guidance. The takeaway for HCA is that the pressures it felt are at least partly industry-wide, but the resulting EBITDA guidance cut was not necessarily inevitable.

HCA called volumes correctly, but got the economics wrong

HCA initially assumed 15%–20% HIX volume attrition for 2026. Of that 15%–20% decline, management further assumed that 15%–20% of affected patients would migrate into employer-sponsored insurance coverage, where hospital economics are generally most favorable, including relative to HIX. HCA also assumed the remainder of affected patients would become uninsured, and that uninsured utilization would fall approximately 30%. Ultimately, HCA estimated that these assumptions would result in a $600M–$900M FY26 HIX headwind, which it intended to partly offset with a $400M “resiliency contribution” (i.e., an enterprise-wide efficiency program). HCA management continued to express confidence in this original framework at multiple intra-quarter conferences all the way through May.

Same-facility HIX equivalent admissions ultimately declined 15% y/y, which was within HCA’s original 15%–20% range. However, the migration of those patients was nearly one-for-one into uninsured (i.e. not 15%–20% into employer-sponsored) and the anticipated utilization reduction did not occur (i.e. not a 30% decline). In total, HCA estimated a $400M 2Q26 HIX headwind inclusive of a $75M upward revision to its original 1Q26 headwind estimate. Graver Research estimates this implies HIX headwinds of $225M in 1Q26 and $325M in 2Q26, or $550M for 1H26—approximately 61%–92% of HCA’s original full-year estimate. As a result, management increased its FY26 HIX headwind estimate from $600M–$900M to $1.0B–$1.2B. At the midpoint, the 2H26 headwind is roughly equal to 1H26, while the implied 3Q26/4Q26 quarterly amount is modestly below 2Q26; at the high end, it equals 2Q26.

Again, it’s important to make the distinction that this reset was principally a coverage-economics miss, and not evidence that patient demand has disappeared. HCA’s admissions, equivalent admissions, and ER visits all strengthened in the quarter. Commercial equivalent admissions excluding HIX also grew 2.4% in the quarter. Still, the HIX migration is not the sole explanation for HCA’s weaker underlying performance as inpatient and outpatient surgeries declined 2.3% and 3.4% in the quarter, respectively. On the call, HCA management acknowledged broader affordability pressure on elective procedures and said HIX was a ‘big piece’ of the surgery declines, but could not quantify the relative contributions despite repeated analyst questions.

Exhibit 1: HCA’s Original 2026 Exchange Assumptions Versus the 2Q26 Update

Weaker 2H26 implied guidance is now the core HCA debate

With the 2Q26 report HCA tightened its adjusted EBITDA guidance range by $200M and lowered the midpoint by $250M, or 1.6%. The revenue guidance range was tightened by $1B, but the midpoint remained unchanged, resulting in an approximately 32 bps decline in the adjusted EBITDA margin midpoint. Diluted EPS guidance is now $0.70, or 2.3%, lower at the midpoint. For the full year, the adjustment points to lower earnings conversion rather than lower revenue expectations. When isolating for the implied 2H26 guidance revenue and EBITDA performance starts to look weaker - more on that later.

The 2Q26 call provided some important details underlying the headline revenue and adjusted EBITDA guidance range revisions. The revised HIX headwind assumption is ~$350M worse at the midpoint, while the assumption for Medicaid supplemental payments improved by ~$550M. The net of those two changes produces a $200M benefit; however, the adjusted EBITDA midpoint was lowered by $250M. This implies another ~$450M of residual headwinds for the full year. Management described that residual as roughly $500M of broader growth moderation but did not decompose it despite a direct analyst question. Surgical mix, professional fees and weaker operating leverage are plausible contributors; whether the full $400M resiliency contribution remains intact is an open question.

1H26 adjusted EBITDA totaled $7.829B on revenue of $39.339B. The revised guidance midpoints therefore imply $7.921B of 2H26 adjusted EBITDA on $38.911B of revenue. That implies particularly weak revenue and EBITDA performance in the back half of this year and will start to raise questions about 2027 performance. Excluding 2020–2021, 2H revenue has exceeded 1H in every year since 2015. Reported 2H26 revenue would be the first exception, declining 1.1% versus 1H26; however, 1H26 includes $980M of revenue attributable to pre-2026 Florida program periods. The midpoint also implies 2H26 y/y revenue growth of just 0.6%, a nearly 600 bps slowdown vs the 6.5% 1H26 revenue growth performance. At the midpoint 2H26 adjusted EBITDA is expected to fall 0.8% y/y. On a reported basis, guidance surprisingly implies 1.2% adjusted EBITDA growth and 46 bps of margin expansion in 2H26 versus 1H26. Excluding 2020–2021, 2H adjusted EBITDA margins have declined by an average 16 bps versus 1H since 2015, although the Florida catch-up distorts the 2026 sequential comparison. That discrepancy will create questions for investors. HCA management is strong, but has it provided enough cushion in the new guidance to avoid another cut?

Exhibit 2: HCA’s Implied 2H26 Guidance Requires Margin Expansion Despite a Sequential Revenue Decline

How the Florida Medicaid program impacted the quarter

Turning to the 2Q26 performance specifically, revenue was $20.230B up 8.7% y/y. Adjusted EBITDA was $4.027B, up 4.6% y/y, while margin declined 78 bps to 19.9%. Revenue and EBITDA beat pre-print consensus estimates by 3.9% and 1.9% respectively, which was already known from the July 14 preliminary update. Adjusted EPS increased 11% y/y while adjusted net income only increased 2.1%, with the share count decline providing substantial support.

The quarter’s reported performance was supported by HCA’s recognition of $1.372B of Florida program revenue. That included $829M of related program expenses, resulting in a $543M adjusted EBITDA benefit for the quarter. Of the totals recognized, $980M, or 71%, of revenue and $423M, or 78%, of the net benefit were related to pre-2026 periods. It’s important to note that the program is a core and ongoing part of its business, and what is being highlighted here is just the period-attribution and catch-up timing. That said, these sort of out-of-period payments can be common with state Medicaid supplemental payment programs which have grown significantly in recent years as a whole and as a percentage of hospital reimbursement. As these programs have grown, it has made isolating pure in-quarter performance and y/y compares more difficult.

Even so, creating sensitivities around performance by removing the out-of-period portions of these payments is still a useful exercise. Removing only the pre-2026 net benefit of $423M produces approximately $3.604B of 2Q26 EBITDA, an 18.7% margin, and a 6.4% y/y EBITDA decline. Mechanically allocating the full $980M to same-facility revenue would lower revenue per equivalent admission growth from 6.4% to approximately 1.2%; however, HCA did not disclose the precise same-facility allocation. To be clear, these calculations are not “normalizations,” but sensitivities. A full normalization would also require adjusting 2Q25 for unquantified retrospective Medicaid supplemental-payment benefits and accrual timing, which cannot be done cleanly given current disclosures. However, we can conclude that while the headline figures for the quarter overstate momentum, the sensitivity analysis performed here also does not establish a precise normalized underlying growth rate– the truth likely lies somewhere in between.

Exhibit 3: Most of Florida’s 2Q26 Benefit Was Related to Prior Periods

Panel A: Florida program recognition recorded in 2Q26

Panel B: Pre-period-excluded 2Q26 sensitivity

Volumes held up, but worse mix negatively impacted earnings

2Q26 same-facility admissions grew 2.5%, equivalent admissions grew 2.7%, and ER visits grew 3.6%. That represents acceleration from 0.9%, 1.3%, and 0.3% in 1Q26, respectively. Commercial equivalent admissions excluding exchanges also increased 2.4% in the quarter. All of this supports HCA’s claim that demand remains healthy at a broad level.

The issue is that, within that broader demand, the underlying mix of services has weakened. Same-facility inpatient surgery cases declined 2.3%, and outpatient surgery cases declined 3.4%. Surgery cases are generally one of, if not the, most important revenue and profit drivers for hospitals, so the decline is an important trend to monitor. Looking deeper, 1H26 elective inpatient surgery cases fell approximately 6%, while emergent surgery cases increased 2%. Roughly 90% of outpatient surgery cases are elective. Management said lost exchange volume was a ‘big piece’ of the surgery weakness but could not separate it from broader affordability pressure.

As stated previously, HIX equivalent admissions declined 15% while uninsured volumes increased by approximately 15%. Uninsured patients now represent more than 10% of equivalent admissions, compared to 6.8% for HIX patients. That one-for-one patient switch at similar service levels creates substantially worse reimbursement and collection economics for HCA. Contracted rate and government update benefits helped offset some of that pressure, but again the Florida program accounting obscures reported revenue intensity.

When considering Medicaid supplemental-payment programs, management said same-facility cost per equivalent admission was approximately flat y/y and improved 1.4% sequentially. Salary and supply growth remained controlled, however professional fees, which reside in the other operating expense line item, increased 8.5%. That increase was primarily led by anesthesia and radiology, after roughly 10% 1H26 growth. Core labor and supply trends were controlled, but mix and professional fees limited operating leverage in the quarter and first half of the year.

THC confirms the mix pressures, but had more cushion and levers to pull

THC reported same-hospital admissions growth of 2.3% and adjusted admissions growth of 2.6%. Management also said Hospital-segment HIX admissions declined 13.5%, with approximately 80%–100% of the lost volume migrating to uninsured. Same-hospital inpatient surgery cases fell 1.9% and it also saw professional fees increase approximately 10%. THC corroborated the principal demand, coverage/mix dynamics, and cost pressures described by HCA, but the EBITDA performance at least versus consensus expectations and prior guidance was materially better.

THC reported 16.3% consolidated EBITDA growth and 22.3% hospital-segment EBITDA growth, with hospital margin expanding 240 bps y/y. It also raised EBITDA guidance by $295M at the midpoint. Even after deducting the full $92M prior-period Medicaid benefit, THC’s adjusted EBITDA would remain approximately 6.3% above consensus and 8.1% above reported 2Q25. That is all in stark contrast to HCA’s $250M reduction to its EBITDA guidance at the midpoint.

To be fair to HCA, THC has significant exposure to USPI, its ASC business, different geographies, and different exchange concentration. It also uses different definitions for key items and different Medicaid accounting. The real conclusion here is that the hospital environment alone did not dictate HCA’s outcome, but its exposures, starting assumptions, service mix, and expense conversion mattered greatly.

Exhibit 4: HCA and THC 2Q26 Operating Comparison

What matters from here

HCA closed July 24 up 1.5%, but still down 2.2% since just before the preliminary update and guidance cut were announced on July 14. The final figures in the report matched the preliminary update. The one-day positive move with the full report on July 24 likely came from a mix of relief that no further cut emerged, improved clarity on the moving pieces, and potentially some THC sympathy.

What matters most from here is: gaining a better understanding of the composition of the $450M–$500M residual reduction to EBITDA guidance; whether the $400M resiliency contribution remains intact; HIX and uninsured mix and service intensity/utilization; progression of elective surgery cases; and evidence supporting 4Q26 growth over 3Q26 and the right 2027 exit rate or jump-off. Further 2027 exchange attrition and potential impacts of Medicaid work requirements will also start to come into focus as we move through the year. For now, long-term demand appears to remain intact, but near-term confidence in earnings conversion and management’s recovery cadence has weakened.

Subscribe now

On the first debate, the evidence points more toward mix pressure than an outright decline in demand. MOH underestimated the concentration of high-cost members in a deliberately smaller Marketplace book. THC, CYH and DGX indicate that many patients losing exchange coverage continue to use healthcare services, often with a less favorable payer profile. The operating pressure is visible across the system, but the earnings impact and stock reaction depends on each company’s starting assumptions, exposure, pricing, service mix and cost execution.

THC provides the most directly comparable read-through to HCA. Its admissions, uninsured-mix and inpatient-surgery trends closely resembled HCA’s preliminary results, yet Tenet delivered a large underlying beat and raised guidance. The release supports HCA’s account of the operating environment, but it does not support treating HCA’s negative EBITDA reset as the default outcome for the hospital group.

The managed-care signals are more company-specific. MOH’s Medicaid results are most relevant to CNC and broadly consistent with ELV’s outlook: cost pressure remains elevated but stable, and improving 2027 rate support reinforces the case that 2026 marks the margin trough, although neither company has shown that recovery is underway. MOH’s Marketplace miss is a real adverse-selection warning for ELV, but not a direct contradiction of ELV’s 2Q ACA upside. The companies entered the year with different, only partly disclosed earnings baselines, and ELV’s upside was not clean evidence of better current-year claims experience. For UNH, MOH’s improved dual-eligible Medicare performance is directionally consistent with UnitedHealthcare’s stronger 2Q Medicare result. Neither company’s performance, however, establishes a broader MA cost-trend inflection.

On the second debate, MEDP and TMO both reported improving biopharma customer activity. The breadth of TMO’s commentary and the recovery in MEDP’s RFP environment make the external demand setup more constructive for IQV, although neither result provides a reliable point estimate for IQV bookings.

Exhibit 1: The six reports matter most for CNC, HCA and IQV

The reports directly inform three coverage debates; implications for other covered names are narrower or more company-specific

Subscribe now

Coverage attrition is changing who pays—and who remains insured

MOH entered 2026 expecting a sharply smaller but profitable Marketplace business. Average pricing increased approximately 30%, while membership declined 59% year over year to roughly 280,000, and the company targeted an 85.5% MCR and a 1.7% pretax margin. First-quarter performance appeared to validate that setup: the normalized MCR was 79.5% and in line with plan.

Second-quarter claims exposed a flaw in the original assumption. MOH had priced for adverse selection, but the remaining book retained more members with high-cost drugs, oncology care and HIV treatment than expected. Risk adjustment did not fully offset those claims. The company increased its Marketplace MCR outlook ~450 bps to approximately 90% and lowered the segment’s contribution by $1.50 per share, from a $0.75 profit to a $0.75 loss.

The headline loss overstates the current-year deterioration. Management attributed approximately $1.00 per share of the revised $0.75 loss to prior-year items and still expects roughly $0.25 of profit from 2026 activity. Even so, the current-year outlook weakened by approximately $1.00 per share, and MOH plans to reduce the business by another $1 billion in 2027. Its 2026 experience is therefore relevant as an adverse-selection case study, not as a representative industry sample. Management noted that MOH has only about 1% of industry-wide Marketplace enrollment.

ELV’s result does not provide a clean counter-signal. ELV also priced for higher morbidity after the expiration of enhanced subsidies, but it did not disclose a comparable starting MCR or margin. Management said after both the first and second quarters that the risk pool was developing broadly in line with its assumptions. The approximately $0.25 of ACA upside reported in 2Q included bronze-plan seasonality and favorable final 2025 risk adjustment; most of the risk-adjustment benefit was re-established in the 2026 accrual.

The comparison is still useful, but for a narrower reason. MOH shows that large rate actions and deliberate membership contraction do not eliminate selection risk. ELV shows that the financial outcome also depends on what was embedded in the starting forecast. Pricing, geography, metal-tier mix, risk adjustment and the initial morbidity assumption remain critical. Available disclosures do not establish whether MOH’s pressure is sector wide.

Provider results show where some displaced utilization is landing. CYH said most patients who lost exchange coverage continued to use its hospitals as self-pay. Self-pay and uncompensated visits increased from just under 5% to more than 6%, and approximately half of adjusted-admission growth came from uninsured encounters that produced little net revenue. CYH now expects a $50–$75 million full-year HIX-related EBITDA headwind.

DGX saw a similar selection effect without the same collections pressure. The company estimated ACA enrollment had fallen more than 20%, while related requisitions declined only 8%. Tests per requisition rose 6%, leaving test volume down roughly 2% and revenue approximately flat. Patient collections and bad debt remained stable. The patients who retained coverage, or continued to seek testing after losing it, used more diagnostic services per encounter.

These observations support HCA’s explanation that exchange disenrollment increased uninsured utilization and reduced the economics of otherwise healthy patient traffic. They do not imply that all providers face the same earnings pressure. Diagnostics, ambulatory care and acute-care hospitals have different exposure to payer mix, acuity and collection risk.

Medicaid pressure looks stable; recovery still has to be earned

MOH increased its 2026 adjusted EPS floor by $0.25 to $5.25, but the segment bridge was volatile. Medicare improved by $1.50 per share, Medicaid improved by $0.25, and Marketplace deteriorated by $1.50.

Medicaid cost trend remained approximately 5% against roughly 4% rate growth. The second-quarter MCR rose to 92.7% from 92.0% in the first quarter, although management described utilization as high and stable rather than worsening. Behavioral health, specialty pharmacy, outpatient professional services and inpatient care remained the main pressure points. MOH still expects only a 1.2% Medicaid pretax margin in 2026, and approximately 55% of its premium does not reprice until January 1, 2027.

The read-through is most relevant to CNC. Stable utilization and improving state rate actions support the view that 2026 can mark the trough in Medicaid margins. They do not establish an inflection in current profitability. The timing of rate resets, mix of state programs and benefit design make exact MCR comparisons unreliable.

MOH’s experience is also consistent with ELV’s unchanged outlook for an approximately negative 1.75% Medicaid margin. Both companies describe cost pressure as elevated but no longer accelerating, with stronger rate support ahead. Neither has yet produced evidence of a sustained margin recovery.

Medicare was better, but product-specific. MOH lowered expected cost trend in its dual-eligible business to approximately 4% from 6%, supporting $1.50 per share of upside. Traditional MA-PD still represents an estimated $1.00 per-share loss and will be exited. The duals improvement is directionally consistent with UNH’s better Medicare performance. It does not establish a broad utilization inflection for HUM or CVS.

THC confirms HCA’s operating pattern—not its earnings outcome

Tenet and HCA reported strikingly similar hospital volume trends. THC’s same-hospital admissions and adjusted admissions increased 2.3% and 2.6%, respectively, compared with HCA’s 2.5% and 2.7%. Inpatient surgeries fell 1.9% at THC and 2.3% at HCA. Tenet also saw clear coverage pressure: charity and uninsured admissions increased 70 basis points, related visits increased 90 basis points, and its uncompensated-care ratio rose 330 basis points to 29.6%.

The earnings results diverged. THC’s $1.304 billion of adjusted EBITDA exceeded consensus by 14.4%. The quarter included a $92 million favorable Medicaid supplemental-revenue adjustment related to prior years. Removing the full amount leaves approximately $1.212 billion of EBITDA, still 6.3% above consensus and 8.1% above last year. On the same conservative adjustment, hospital margin was approximately 16.2%, about 60 basis points higher year over year.

Tenet increased the midpoint of 2026 EBITDA guidance by $295 million. The bridge included $140 million of incremental Medicaid supplemental revenue, $97 million of first-half outperformance and $58 million of expected second-half improvement. Excluding the supplemental-payment update, the operating outlook improved by $155 million. The new $4.93 billion midpoint stands 6.4% above prior guidance and 5.8% above pre-print consensus.

The contrast with HCA begins with the starting assumptions. Tenet continues to incorporate a $250 million full-year headwind from the expiration of enhanced premium tax credits. HCA raised its estimate of the same broad pressure from $600–$900 million to $1.0–$1.2 billion and lowered its EBITDA midpoint by $250 million. THC therefore does not refute HCA’s payer-mix explanation. It shows that exposure, prior assumptions, pricing, Medicaid supplemental payments and expense execution can lead to different earnings outcomes in a similar volume environment.

Historical comparability also argues for restraint. From 1Q24 through 2Q26, HCA and THC admissions growth had a correlation of approximately 0.71, but equivalent and adjusted admissions correlated only 0.52; sequential direction matched in four of nine comparisons. CYH was directionally similar over the same period, with correlations of approximately 0.69 for admissions and 0.68 for equivalent or adjusted admissions. Those relationships are useful corroboration, not forecasting tools.

CYH’s surgery data deserve even less weight. Definitions have not been consistent enough for a standardized series, and the companies have diverged in prior quarters. CYH’s current 3.8% decline in inpatient surgeries supports the direction of HCA’s reported mix weakness, but it should not be used to estimate HCA’s future volumes or earnings.

Exhibit 2: THC confirms HCA’s operating pressures, but not its earnings outcome

HCA and THC reported nearly identical admissions and inpatient-surgery trends in 2Q26. Tenet’s underlying beat and guidance increase show that similar operating pressures do not produce a uniform earnings outcome.

Panel A: 2Q26 operating and earnings comparison

Panel B: Historical volume comparison

MEDP and TMO improve the demand setup for IQV

MEDP’s net new awards increased 28% to $796 million, producing a 1.13x book-to-bill ratio. RFP activity improved sequentially and year over year, and management described a broader group of recently funded biotechnology customers. That is constructive after an extended period of uneven funding and cautious trial starts.

The quality of the rebound needs qualification. More than half of the sequential improvement in net bookings came from fewer cancellations rather than higher gross awards. Oncology represented more than half of bookings and award notifications, and several large metabolic programs still influence customer concentration. MEDP is also more exposed than IQV to small and mid-sized biotechnology sponsors.

TMO provides the stronger cross-check because PPD (TMO’s CRO subsidiary) has greater large-pharma and global CRO exposure. Pharma and biotechnology organic growth reached the mid-single digits, led in part by clinical research. Management said clinical-research authorizations had been strong for several quarters and typically require about six months to convert into revenue. Improving biotechnology spending is now appearing in reported growth, and TMO modestly raised its second-half organic-growth assumptions.

The combined evidence raises confidence in a firmer clinical-research demand environment into the second half and 2027. It does not justify a specific IQV book-to-bill estimate or a market-share conclusion. MEDP’s sponsor mix differs, while TMO sells PPD as part of a broader integrated offering. The appropriate read-through is improved end-market direction.

The setup into the print is shaping the stock reaction

At this stage, the tape is better read against what each stock had already priced in and the size and quality of the earnings reset. Consensus revisions remain incomplete and are not yet a useful measure.

ELV and MOH show why the setup matters. From the first close after their 1Q results were fully absorbed to the pre-2Q close, the stocks rose 30.0% and 26.9%, respectively. Both companies then beat quarterly EPS and raised FY26 guidance, yet ELV fell 8.5% and MOH declined 9.7% in the first full post-print session. The headline math was positive, but neither result cleared the bar embedded in the stock. ELV did not show that Medicaid margins had begun to recover, while MOH’s Marketplace reset weakened confidence in its forward earnings base.

UNH provides a useful counterpoint. Shares had gained 21.0% since the post-1Q close before the company delivered a roughly 30% adjusted EPS beat and raised guidance to $19.50–$20.00. The stock gained only 1.2% in the first session, although the cumulative move reached 4.3% through July 21. The result was clean, but expectations had already risen materially.

HCA and CYH are more straightforward guidance reactions. HCA had declined 9.6% since its 1Q report, but the preliminary update lowered the FY26 EBITDA midpoint 1.6% and drove another 6.9% decline. CYH entered its report up 18.8%, delivered only a 1.0% EBITDA beat, cut its guidance midpoint 5.5%, and fell 13.7%.

The positive reactions were backed by cleaner earnings resets. MEDP, TMO and DGX gained 14.7%, 8.7% and 8.6%, respectively, after beating the relevant quarterly measure and raising guidance. MEDP’s move was particularly notable after a 34.2% run-up, suggesting the bookings rebound mattered more than the guidance increase alone. THC was the clearest case: adjusted EBITDA exceeded consensus by 14.4% and the new midpoint rose 6.4%, supporting an approximately 14% after-hours gain. The concurrent moves in HCA and UHS indicate that investors viewed part of Tenet’s result as transferable to the hospital group.

Exhibit 3: The stock reaction reflects both the earnings reset and the pre-print setup

The post-1Q return provides context for the expectations embedded in each stock. The first post-print move then shows whether the quarter and revised outlook cleared that bar.

Implications for core coverage

The highest-value read-throughs are concentrated in three names. For CNC, MOH supports a stable Medicaid cost trend and better 2027 rate support, while highlighting the selection risk in a shrinking Marketplace book. For HCA, THC validates the payer- and surgery-mix pressure but makes HCA’s earnings reset look less transferable across the hospital group. For IQV, MEDP and TMO provide the strongest external evidence this quarter that clinical-research demand is improving.

The evidence for the remaining names is narrower. MOH’s duals performance is consistent with UNH’s stronger Medicare result, but does not resolve the broader MA debate for HUM or CVS. ELV’s Marketplace result cannot be compared with MOH’s without accounting for different starting assumptions. The six reports do not materially change the outlook for CI, MCK or COR.

The next useful evidence will come from the HCA and THC calls. The release-level data already establish the operating pattern; management commentary should determine whether the divergence in earnings was driven mainly by exposure and starting assumptions or by a more durable difference in pricing, service mix and expense execution.

The quarter establishes a higher and more credible earnings base. UnitedHealthcare and Optum Health produced roughly 83% of the $1.75 billion consolidated adjusted operating-earnings upside, and both full-year segment guides moved higher. The offset is commercial cost trend modestly above 11%, which extends full commercial margin recovery beyond 2027. Medicare improved materially, but management did not characterize that performance as a broad utilization inflection.

Exhibit 1. 2Q26 at a glance

Subscribe now

The beat survives the harshest reserve adjustment

The full-removal case is intentionally severe. Management said most of the $860 million related to 2026 dates of service, so treating it as a stale prior-year reserve release would be too punitive. The calculation nevertheless provides a useful earnings-quality bookend: it adds the full amount back to reported medical costs and removes the after-tax EPS impact using the updated 18.5% tax rate and 906 million diluted shares.

The operating upside was also broad enough to survive that adjustment. UnitedHealthcare and Optum Health contributed $822 million and $636 million of variance versus Street expectations, respectively. Optum Insight added $213 million and Optum Rx $100 million. Revenue was only 1.1% above consensus and the 12.7% operating cost ratio was in line, making margin execution—not top-line leverage—the principal source of upside.

Exhibit 2. The 2Q26 Beat Survives a Full Medical Development Normalization

The full-removal case remains favorable to both Street and Graver Research expectations; UnitedHealthcare and Optum Health account for most of the operating-earnings variance

Medicare improved enough to offset a worse commercial trend

UnitedHealthcare was the largest source of upside, with $3.94 billion of operating earnings versus $3.12 billion expected. The full-year floor increased to $12.0 billion from $10.8 billion. Medicare cost trend is now expected below the initial approximately 10% plan, retention was better than anticipated, and management expects Medicare Advantage enrollment to decline by roughly 1.1 million while margins finish above 3%. Benefit design, care management and network actions drove much of the improvement, although respiratory season, weather and favorable development also helped. Medical trend remains well above historical levels.

Commercial moved in the opposite direction. Cost trend is now modestly above 11%, with the No Surprises Act dispute-resolution process contributing roughly 50 basis points of incremental 2026 trend and at least 100 basis points in total. Higher coding intensity, cost per encounter and specialty-drug pressure are additional drivers. Management now expects full commercial margin recovery after 2027. Medicaid performance was broadly in line, with the 2026 margin outlook unchanged at negative 1.0% to negative 1.7%. The UnitedHealthcare guide raise is therefore Medicare-led; commercial remains the largest insurance-side uncertainty.

Optum Health was the second real positive; Insight included timing

Optum Health generated $1.174 billion of adjusted operating earnings versus $538 million of Street consensus and the $509 million Graver Research estimate. Its adjusted full-year floor increased to $2.215 billion from $1.577 billion. Clinical and operating improvements appear tangible—management cited an approximately 10% reduction in inpatient admissions from one scaled care-management initiative—but the quarter should not be annualized. Nearly all Optum Health earnings are expected in the first half, with a modest third-quarter profit offset by a modest fourth-quarter loss.

Optum Insight also beat, with $1.373 billion of adjusted operating earnings versus $1.160 billion expected, but some client transaction volume moved from the second half into the first. Its $4.75 billion adjusted full-year floor is unchanged. Optum Rx produced $1.490 billion versus $1.390 billion expected and retained its $6.25 billion guide. Both businesses remain approximately 55% second-half weighted. The formal 2026 reset is therefore concentrated where the operating evidence was strongest: UnitedHealthcare and Optum Health.

Exhibit 3. The 2026 Guidance Reset Is Concentrated in UHC and Optum Health

The adjusted segment operating-earnings floor increased by approximately $1.84 billion, entirely from UnitedHealthcare and Optum Health. First-half adjusted EPS of $13.61 implies a second-half midpoint of only $6.14.

A higher base, not a higher second-half run rate

Updated adjusted EPS guidance of $19.50 to $20.00 is well above the prior floor of $18.25, but the cadence remains back-end light. First-half adjusted EPS of $13.61 leaves $5.89 to $6.39 for the second half, or $6.14 at the midpoint. Management expects slightly more earnings in the third quarter than the fourth; UnitedHealthcare remains roughly 75% first-half weighted and Optum Health nearly entirely first-half weighted, while Insight and Rx provide the second-half offset.

The refreshed Bloomberg cadence confirms that the Street has not extrapolated the 2Q beat into a higher second-half run rate. Third-quarter EPS consensus increased to $4.02 from $3.70, while fourth quarter declined to $2.23 from $2.61; aggregate second-half EPS is essentially unchanged at $6.25 versus $6.31 pre-print. FY26 and FY27 consensus increased 6.5% and 6.1%, respectively. The FY27 segment revision is concentrated in UnitedHealthcare and Optum Health, which increased by approximately $1.00 billion and $485 million; Insight rose only $41 million and Rx declined $61 million.

Management described the $19.50 to $20.00 range as a durable stepping-off point for its 13% to 16% long-term growth algorithm, while acknowledging that the range includes favorable medical development. Current FY27 consensus of $22.32 represents 13.0% growth from the 2026 midpoint—effectively the low end of that framework. The estimate reset is credible, but delivery still depends primarily on insurance execution and Optum Health rather than a near-term acceleration in Insight or Rx.

Exhibit 4. Consensus Carries the Reset into 2027, Not into 2H26

Post-print consensus shifts earnings from 4Q into 3Q but leaves aggregate second-half EPS essentially unchanged. The FY27 operating-earnings revision is concentrated in UnitedHealthcare and Optum Health.

The market raised the earnings base without expanding the multiple

UNH entered the print with a demanding setup: shares rose 21.0% from April 21 through the July 15 pre-print close, versus 7.2% for the S&P 500 and 8.5% for XLV. Through July 21, the stock gained 4.3% while FY27 EPS consensus increased 6.1%, reducing the implied FY27 P/E from 19.9x to 19.5x. The earnings reset outpaced the stock; commercial trend and reserve quality prevented multiple expansion.

Reserve quality is supportive, but the 10-Q still matters

Release-level balance-sheet indicators lean supportive: medical costs payable increased 1.3% year over year while premium revenue declined 1.1%, and days claims payable of 47.0 was 2.5 days above 2Q25. DCP declined sequentially, which management attributed to normal seasonality. Without the incurred-period roll-forward, the reserve cushion cannot be fully reassessed until the 10-Q is filed.

Investment conclusion. The 2Q print confirms that the rebuild can produce cleaner earnings and a higher baseline, supported by real improvement in Medicare and Optum Health. It does not establish a broad medical-cost inflection. Further re-rating likely requires commercial pricing to catch up to trend, Medicare margins to survive the 2027 bid cycle, Optum Health to hold through the weaker second half, and the 10-Q reserve roll-forward to support the release-level indicators.

The problem was less the quarter than the path forward. July Medicaid rate updates were better than expected, membership and acuity were broadly in line, and management described the cost pressures as elevated but understood. Yet the full-year Medicaid operating margin outlook remained approximately negative 1.75%, management is not assuming material medical-cost trend improvement in the second half, and ELV expects additional market exits. The market wanted proof that better rates and operating actions were translating into margin recovery; 2Q26 offered a better setup, but not that proof.

Exhibit 1. 2Q26 at a glance

Subscribe now

The beat was real — just not fully recurring

The cleanest way to read the quarter is in three layers. First, reported adjusted EPS was $7.45. Second, removing the approximately $0.80 net below-the-line benefit produces roughly $6.65, still 7.1% above consensus. Third, management said operating outperformance was approximately $0.50, split about evenly between Medicare Advantage and Individual ACA. That makes the result meaningfully better than a one-time-assisted headline beat.

The tension is that strong benefit expense performance did not translate into year-over-year earnings growth. The 89.7% benefit expense ratio was 30 basis points better than StreetAccount consensus, but adjusted operating gain still declined 26.9% to $1.82 billion and adjusted operating margin fell 140 basis points to 3.6%. Health Benefits operating margin declined 170 basis points to 2.1%. In other words, the quarter beat a low bar while the underlying earnings base remains well below last year.

The guide rose to $27, but the recurring baseline is $26

ELV raised 2026 adjusted EPS guidance by $0.25 to at least $27.00, versus the $26.87 pre-print consensus. The full bridge is more informative than the headline. Management’s recurring earnings baseline increased from at least $25.75 to at least $26.00; approximately $0.25 of 2Q seasonality is expected to reverse in the second half, while $0.25 of operating strength is retained. The approximately $0.80 second-quarter below-the-line benefit is being redeployed into accelerated one-time investments and therefore contributes nothing net to the full-year guide.

The remaining $1.00 gap between the $26.00 recurring baseline and the $27.00 reported guide reflects the non-recurring investment-income benefit recognized in the first quarter. The raise is therefore recurring, but the reported guide is not the correct jumping-off point for 2027.

Exhibit 2. ELV’s $27 guide contains a $26 recurring earnings baseline

The bridge separates operating improvement from timing and non-recurring items. It also shows why the 2027 growth target begins at $26.00 rather than the reported $27.00 guide.

At least 12% growth from the $26.00 baseline implies a 2027 EPS floor of $29.12. That is only 7.9% above the reported 2026 guide. Current 2027 Bloomberg consensus is at $29.50, just $0.38 above management’s floor. The 2027 target is achievable on paper, but it leaves little room for slippage in the Medicaid recovery, Carelon growth, operating efficiency, or capital deployment assumed to support it.

Medicaid was not worse — but it was not better enough

The negative 1.75% Medicaid margin outlook is not new. ELV established it with fourth-quarter results in January, maintained it after the strong first-quarter print, and maintained it again in 2Q26. That continuity matters: the second quarter did not reveal a new acuity shock or a new step-up in cost trend. Management said membership and acuity remained broadly aligned with expectations, while the principal cost drivers — behavioral health, including ABA therapy; emergency department utilization; outpatient surgery; and specialty pharmacy — were familiar and actionable.

The disappointment is that the better rate picture did not change the full-year margin. July 1 rate updates moved toward the upper end of a mid-single-digit range, versus the lower end assumed at the start of the year. ELV expects the second-half margin to improve from 2Q26 as those rates and cost actions take hold, but it is not assuming material improvement in medical-cost trend. The company also confirmed its D.C. exit and expects to leave additional Medicaid markets over the next 12 to 18 months where it does not see a path to sustainable returns.

Our interpretation is that management is preserving room for volatility rather than signaling a hidden step-down in the business. Even so, unchanged guidance after better rates creates a burden of proof: either the rate upside is being absorbed by continued utilization pressure, or the company is holding conservatism that needs to convert into later upside.

Exhibit 2. Every 50 bps of Medicaid margin recovery is worth about $1.00 of EPS

At ELV’s current Medicaid revenue base, even partial margin recovery is material to the 2027 earnings algorithm. The sensitivity below illustrates why investors are focused so heavily on this one segment.

H1 Medicaid operating revenue was $28.72 billion, or a $57.45 billion annualized run rate. On that base, 50 basis points of margin recovery equates to approximately $287 million of operating income and $0.99 of after-tax EPS. A 100-basis-point recovery would contribute roughly $1.99 of EPS, or 64% of the $3.12 increase needed to reach the $29.12 floor. Full recovery from negative 1.75% to breakeven would be worth approximately $3.48 of EPS before considering revenue changes, market exits, or reinvestment. That is not our forecast, but it shows the scale of the embedded earnings drag — and the potential leverage if the turn materializes.

MA and ACA improved; Carelon was steady

Medicare Advantage. The deliberate 2026 portfolio reset is working. Favorable membership mix, better claims experience, and a greater concentration in D-SNP and HMO products generated roughly half of the quarter’s $0.50 operating outperformance. ELV remains on track for at least a 2% MA operating margin in 2026.

Individual ACA. The other half of the operating upside came from Individual ACA. A heavier mix of bronze plans produced more favorable early-year seasonality, and final 2025 CMS risk-adjustment results were better than estimated. ELV re-established the vast majority of that prior-year favorability in its 2026 accrual rather than extrapolating it, which explains why the quarter’s face-value upside did not flow through fully to guidance.

Carelon. Revenue increased 6.3% to $19.2 billion and operating gain increased 1.3% to $0.9 billion, while margin declined 30 basis points to 4.9%. CarelonRx benefited from specialty-pharmacy profitability, while Carelon Services continued to absorb investment as newer risk-based programs scale. The segment remains an important 2027 lever, but 2Q26 was steady rather than thesis-changing.

The stock reaction was a multiple reset, not an estimate reset

ELV entered the print with a demanding setup. Shares were up 30.1% from the April 21 close through July 14, versus 6.8% for the S&P 500 and 8.5% for XLV. The stock then fell 8.5% on July 15 and another 4.5% on July 16 before finishing essentially flat on July 17—a cumulative decline of 12.6% from the pre-print close.

Estimate revisions, however, were modest and positive—broadly consistent with the $0.25 guidance increase. Bloomberg consensus for 2026 EPS has risen $0.19 to $27.09, while 2027 consensus has increased $0.23 to $29.50. That disconnect indicates that the selloff was a multiple reset driven by execution risk and reduced earnings visibility, not a material reduction in expected earnings. That is the most important market message from the event.

Our take

We view 2Q26 as a fundamentally better quarter than the stock reaction implies, but not as proof that the Medicaid turn has arrived. The normalized EPS beat, MA progress, ACA execution, stronger Medicaid rates, and higher cash-flow guide are all constructive. Against that, the unchanged negative 1.75% Medicaid margin, the absence of assumed second-half cost-trend improvement, and the planned market exits keep the central earnings-quality debate unresolved.

The selloff reset the burden of proof. If second-half Medicaid margins improve as rates flow through, the $26 recurring baseline should support the $29.12 2027 floor and the current valuation could prove too punitive. If rate gains continue to be absorbed without visible margin progress, the market will question not only Medicaid’s recovery, but also how much of the 2027 algorithm must be supplied by Carelon, expense efficiency, and capital deployment.

What we are watching. The key evidence points are the 3Q26 Medicaid margin, the exit rate entering 2027, the scope of planned market exits, the durability of MA’s at least 2% margin, and measurable benefits from the one-time investments.

Preliminary revenue of $20.23 billion increased 8.7% year over year and was 3.9% above FactSet consensus. Adjusted EBITDA of $4.03 billion increased 4.6% and was 1.9% above consensus. Nevertheless, adjusted EBITDA margin declined roughly 80 basis points to 19.9%. HCA also reduced the midpoint of its 2026 adjusted EBITDA guidance by $250 million, or 1.6%, to $15.75 billion from $16.0 billion. All figures remain preliminary ahead of the July 24 earnings report.

Subscribe now

The headline beat was not a clean measure of operating momentum

Two roughly $400 million items shaped the quarter.

First, HCA estimated that the shift from health insurance exchange (HIX) coverage to uninsured status reduced second-quarter pretax income by approximately $400 million. That amount included a $75 million increase to the company’s prior estimate of the first-quarter impact.

Second, HCA recognized approximately $400 million of incremental Medicaid supplemental payment benefit, primarily related to Florida. The benefit covered October 1, 2024, through June 30, 2026, following approval of the state’s directed payment program.

The two items were similar in size but very different in character. The Florida benefit spans multiple reporting periods and therefore includes a substantial timing or catch-up component. The exchange headwind reflects the current economics of HCA’s payer mix and is embedded in the revised full-year outlook.

To frame the sensitivity, deducting the entire $400 million incremental Medicaid benefit from preliminary adjusted EBITDA yields approximately $3.63 billion, 8.2% below the preannouncement Street estimate and 5.8% below 2Q25. We would not treat $3.63 billion as normalized because some portion of the Florida benefit may recur. The exercise nevertheless shows why the preliminary $4.03 billion should not be treated as a clean quarterly run rate.

Patient traffic recovered, but surgical activity moved in the opposite direction

Exhibit 1. Broad patient traffic reaccelerated in 2Q26

Exhibit 2. Surgical volumes weakened despite higher admissions

Exhibits 1 and 2 highlight the key distinction. Broad patient traffic improved materially from 1Q26: admissions accelerated from 0.9% to 2.5%, equivalent admissions from 1.3% to 2.7%, and ER visits from 0.3% to 3.6%. The data therefore do not point to a system-wide demand contraction.

Surgical activity tells a different story. Inpatient surgery growth deteriorated to negative 2.3% in 2Q26 from negative 0.3% in 1Q26, while outpatient surgery growth weakened to negative 3.4% from negative 1.7%. Both were the weakest readings in the ten-quarter series.

The 4.8-percentage-point gap between admissions growth and inpatient surgery growth was also the widest in the period shown. The divergence is consistent with HCA’s description of a service-mix shift: hospitals saw more patients, but fewer encounters translated into surgical cases. That effect compounds the payer issue because elective and commercially insured surgical activity generally carries more favorable economics than uninsured or lower-acuity traffic.

The guidance bridge suggests a broader reset

The midpoint of revenue guidance remains unchanged at $78.25 billion, while the adjusted EBITDA midpoint declined by $250 million. On midpoint math, that implies roughly 30 basis points of lower EBITDA margin and reinforces that the reset is about conversion and mix rather than aggregate revenue.

Exhibit 3. Disclosed policy changes do not explain the full EBITDA guide cut

The two disclosed assumption changes produce a net $200 million benefit, yet the adjusted EBITDA midpoint fell by $250 million. The difference is an implied $450 million residual.

This is our calculation, not a company-provided bridge, and we would not label the entire residual “core” before the earnings call. It could reflect service mix, other operating assumptions, rounding, and any unquantified change in the expected contribution from HCA’s resiliency initiatives. Still, it is the most important unanswered question in the update, particularly because HCA also cited improved expense trends.

Using the revised midpoint, HCA’s preliminary first-half results imply approximately $7.92 billion of adjusted EBITDA in 2H26, roughly 0.8% below the $7.98 billion generated in 2H25. Put differently, the midpoint no longer assumes year-over-year adjusted EBITDA growth in the second half.

The stock is discounting more than a $250 million guide cut

HCA fell 6.9% on July 14, recovered 4.2% and 1.8% over the next two sessions, and then declined 3.7% on July 17. The shares ended the four-session period down approximately 5.0% from the July 13 close, despite the intervening recovery.

At $371.18, HCA is down 20.5% year to date, 14.2% since the April 24 first-quarter report, and 31.9% from its March 9 closing high of $545.13. The latest Street snapshot shows FY26 adjusted EBITDA of approximately $15.86 billion and FY27 adjusted EBITDA of $16.54 billion. Estimates have therefore moved far less than the share price.

That disconnect suggests the market is applying a larger discount for earnings quality and visibility, rather than simply processing the mechanical $250 million guidance reduction. Investors appear less willing to capitalize Medicaid payment timing and are demanding more evidence that the deterioration in uninsured and surgical mix is stabilizing.

What matters on the July 24 earnings call

The call needs to clarify five issues:

• How much of the $400 million Florida benefit was retroactive, and what portion is representative of the ongoing run rate?

• What was the 2Q26 HIX headwind excluding the $75 million first-quarter true-up, and is that run rate stabilizing?

• Was the surgical weakness concentrated by payer, service line, geography, or facility type?

• What accounts for the approximately $450 million residual in our midpoint guidance bridge?

• Does management remain confident in the previously discussed $400 million resiliency contribution?

Our preliminary conclusion is that broad hospital demand remains intact, but HCA’s earnings quality and visibility have deteriorated. The July 24 call can narrow that uncertainty, but the post-announcement price action indicates that investors are not yet willing to treat the headline 2Q26 adjusted EBITDA result as durable.

UnitedHealth Group is the largest and broadest company in healthcare services. With $447.6 billion of 2025 revenue, it spans health benefits, Medicare Advantage, Medicaid, pharmacy services, care delivery, health payments and healthcare technology. That breadth makes UNH relevant to nearly every major sector debate, but the immediate investment question is narrower: has the company reset medical costs, pricing and reserves onto an earnings base investors can again underwrite?

Confidence broke quickly in 2025. UNH affirmed adjusted EPS guidance of $29.50-$30.00 in January, cut the outlook in April and suspended it in May as Medicare Advantage utilization, new-member acuity and broader cost pressure exceeded expectations. By July, guidance had been re-established at only $16.00+, alongside an 89.4% MCR and unfavorable reserve development. The damage was not limited to the earnings reduction; it challenged a long-standing perception that UNH had superior forward visibility and unusually reliable guidance.

Managed-care accounting amplified the reset. Premiums and benefits are established largely in advance, while the related medical costs develop over subsequent months as claims are submitted and processed. Q1 is therefore especially estimate-dependent. When utilization and claims patterns are stable, this lag is manageable; when trend changes, a relatively small forecasting error can have a disproportionate impact on a low-margin insurer. The same annual repricing cycle can also support a rapid recovery if management correctly identifies the new cost base, although Medicaid rate adjustments typically lag.

Q1 2026 was encouraging but not conclusive. Adjusted EPS reached $7.23, the MCR improved to 83.9% and full-year guidance was raised, but the result benefited from favorable reserve development while underlying utilization remained elevated. By the second-quarter report, most Q1 claims will be substantially more developed and management will have an initial read on Q2 utilization. The print is therefore the first meaningful test of whether Q1 completed cleanly, reserves remain prudent and 2026 repricing is translating into durable margin recovery.

Exhibit 1 places that test in context, tracing the break in the prior earnings framework and the early stages of the 2026 recovery.

Exhibit 1. UNH Share Price: From the 2025 Reset to the 2Q26 Test

2Q26 Setup: Validation, Not Yet an Inflection

I expect 2Q26 to validate the Q1 setup rather than mark a new inflection. My estimate is $5.00 of adjusted EPS, 3% above Bloomberg consensus, on revenue of $111.6 billion. The upside is primarily MCR-driven, with UHC and Optum Health above consensus partly offset by modestly lower Optum Insight and Optum Rx estimates.

Exhibit 2. UNH 2Q26 Earnings Setup

My 88.3% MCR estimate is 15 basis points favorable to consensus and assumes modest favorable prior-period development as Q1 claims complete. It does not assume a material reduction in current medical cost trend. The expected read-through is that Q1 reserves were established prudently and that elevated utilization remains within the assumptions embedded in 2026 pricing.

At the segment level, I estimate $3.28 billion of UHC operating earnings at a 3.8% margin and $509 million of adjusted Optum Health operating earnings. My Insight and Rx estimates are slightly below consensus, reflecting their heavier second-half earnings cadence and continued investment and implementation costs.

At $5.00, first-half adjusted EPS would total $12.23, or 67% of the current $18.25 guidance floor - consistent with management’s expectation that roughly two-thirds of annual earnings will be generated in the first half. The setup is fundamentally constructive, but the stock has rerated materially since Q1. A clean validation print may support the recovery thesis without producing another outsized positive reaction; the hurdle for incremental upside is now better current-period trend, preserved reserve conservatism or a more substantive guidance raise.

Claims Completion and Reserve Quality: The Core 2Q Test

The reported MCR will matter less than the evidence beneath it: how Q1 claims completed, whether any favorability reflects reserve development or current-period trend, and what reserve position UNH carries into the second half.

Medical costs payable includes claims incurred but not yet received or processed. For recent service periods, UNH estimates the ultimate obligation using trend assumptions and completion factors - the percentage of claims expected to be visible at a given point. The company notes that billing lags can extend to 90 days and that approximately 90% of claims are known and settled within that period. A March 31 balance therefore still includes substantial estimation around February and March care activity; April and May provide a much more complete view.

That lag is benign when utilization, unit costs and submission patterns are stable, but it can create substantial earnings volatility when those relationships change. UNH’s 2025 experience is the relevant precedent: higher MA activity became visible late in Q1, then broadened as claims developed. By 2Q25, the company reported an 89.4% MCR and $70 million of unfavorable reserve development, nearly all tied to 2025 service dates.

The reserve position entering 2Q26 looks materially more conservative than a year ago.

Exhibit 3. UNH Enters 2Q26 With a More Conservative-Looking Reserve Position

Panel A. Medical Costs Payable Growth Outpaced Premium Growth by 561 bps in 1Q26

Panel B. Selected Reserve Indicators Entering 2Q26

UNH ended Q1 with $39.7 billion of medical costs payable, up 6.8% year over year, versus premium growth of only 1.2%. The resulting +561-basis-point reserve-growth spread compares with an ex-COVID historical average of +6 basis points; it is the strongest Q1 reading in my series back to 1Q19 and the second-highest non-COVID quarterly observation. DCP rose 3.1 days year over year to 48.6, while the roll-forward showed $1.05 billion of gross favorable prior-year development versus $320 million in 1Q25. Management characterized the net enterprise benefit as slightly above $500 million and said it had re-established a similarly prudent reserve position at March 31.

These metrics are supportive, not dispositive. Faster reserve growth may reflect added conservatism, but it can also reflect a larger underlying claims liability; DCP is also affected by mix, payment timing and Part D mechanics. The 2Q report therefore needs to establish three points: Q1 claims complete without adverse current-year development; current utilization remains within pricing assumptions; and the June reserve position stays prudent after any favorable development is recognized.

My 88.3% MCR estimate assumes modest favorable development and no material improvement in underlying trend. The highest-quality outcome is not simply a lower MCR, but a return to the operating pattern that historically supported UNH’s earnings consistency: cautious initial estimates, favorable claims development and sufficient reserve cushion for the seasonally more difficult second half.

UHC: Testing the Pricing Reset

UnitedHealthcare (UHC) is the clearest path to 2026 earnings recovery. At the July 2025 reset, management estimated medical costs were $6.5 billion above the original plan - $3.6 billion in Medicare, $2.3 billion across commercial and exchange products and the balance in Medicaid. The 2026 response is straightforward: price and design products around the higher cost base, accept membership contraction where returns are inadequate and restore margins before pursuing growth.

The recovery does not require medical trend to normalize; it requires pricing to remain ahead of an elevated trend environment. In MA, UNH entered 2025 with pricing based on just over 5% trend, versus an eventual 7.5% outcome. The 2026 bids assume trend approaching 10%. That is not a simple 250-basis-point cushion: roughly two-thirds of the increase reflects known provider-rate and fee-schedule changes, while the remainder accommodates less predictable risks. Residual utilization is assumed to remain high but stable.

The early evidence is favorable. Management described Q1 MA trend in the 7%-8% range against the approximately 10% pricing assumption, with modest favorability across government programs continuing through April. UHC’s Q1 operating margin increased 40 basis points year over year to 6.6%, despite MA and commercial risk membership contraction. My 2Q estimate of $3.28 billion of operating earnings and a 3.8% margin assumes that pricing alignment continues without a further trend inflection.

For Medicare, a clean quarter should preserve the expected roughly 50-basis-point margin recovery while MA membership contraction remains near 1.3 million lives. The volume loss largely reflects deliberate plan exits, benefit changes and a shift away from less manageable products. The appropriate trade-off is lower membership with adequate pricing rather than another year of volume retention at subeconomic margins. The warning sign would be attrition moving materially beyond plan without the expected margin benefit.

Commercial follows the same framework. Group trend remains near 11%, and the risk book has been repriced accordingly. At March 31, commercial risk membership was down 685,000 year over year while fee-based membership increased 750,000, reflecting both pricing discipline and migration toward self-funded products. More than 500,000 of the risk decline relates to the exchange business, which is small in the context of UNH earnings. The more important test is whether group renewals continue to close the margin gap without materially worse retention.

Medicaid remains the exception. State rate updates lag acuity and trend, limiting UHC’s ability to reprice on its own timetable. Management entered 2026 assuming 6%-7% aggregate rate increases but still expects rates to remain below trend, leaving the business in a loss position this year. April 1 and July 1 rate actions will be important, but Medicaid is unlikely to contribute meaningful upside.

The current evidence supports pricing ahead of trend in Medicare and commercial, but not Medicaid. Q2 needs to confirm that elevated utilization remains within the new assumptions, margin recovery is arriving alongside the planned membership contraction and the pricing cushion has not begun to erode.

Optum: Segment Cadence Matters

Optum is unlikely to determine whether the consolidated print is fundamentally clean; medical costs and reserves remain the primary drivers. It can, however, materially affect earnings quality. Optum Health, Insight and Rx have different seasonal profiles, so sequential growth is a poor common benchmark.

Optum Health reported $1.31 billion of adjusted operating earnings at a 5.4% margin in Q1 - more than 80% of the initial full-year adjusted floor of $1.58 billion. That is not a sustainable quarterly run rate. Following the transfer of Optum Financial to Insight, Optum Health more closely resembles a risk-bearing care-delivery business and is heavily first-half weighted. My $509 million estimate at a 2.2% margin therefore assumes a deliberate sequential decline, not renewed deterioration.

The quarter should be assessed on a clean adjusted basis. Reported 2026 guidance includes $623 million of earnings from amortizing the loss-contract reserve established in 4Q25, while adjusted guidance excludes that benefit. The accounting amortization does not represent current-year operating improvement. The key tests are no further contract or portfolio charges, no increase in the reserve and continued progress toward repricing or exiting the affected third-party contracts for 2027.

Insight and Rx are more back-half weighted, with management expecting each to generate approximately 60% of annual earnings in 2H26. At Insight, older products are being decommissioned while AI-enabled offerings are developed and commercialized. My $1.06 billion earnings estimate at a 20.1% margin is modestly below consensus; a small shortfall would be acceptable if the back-half cadence and new-product sales remain intact.

Optum Rx is absorbing implementation costs for nearly 800 new clients while UHC membership contraction reduces internal volume. My $1.56 billion estimate at a 4.1% margin is also modestly below consensus and the approximately 4.2% full-year target. The relevant read-through is whether onboarding remains on schedule and external wins, productivity and second-half volume can offset the internal membership headwind.

A clean Optum quarter may therefore appear mixed on a sequential basis: a sharp step-down at Health and only partial progress at Insight and Rx. The appropriate test is cadence. Health must deliver a clean step-down without another reset; Insight and Rx must preserve a credible second-half ramp.

Guidance and Capital Deployment

The headline question is whether UNH raises the adjusted EPS floor above $18.25. At my $5.00 2Q estimate, first-half EPS would reach $12.23, or 67% of the current floor, broadly consistent with management’s expectation that slightly under two-thirds of annual earnings will be generated in 1H26. That supports a higher floor if the operating assumptions remain intact.

The source matters more than the size. A raise supported by stable current-period trend, UHC margin recovery and clean Optum execution would de-risk the earnings base. The same increase driven mainly by reserve development, taxes or share-count accretion would be less informative. A modest raise - or even a maintained floor - could still be high quality if management preserves reserve cushion and reinvests some upside.

Capital deployment is a secondary confidence signal. Initial guidance contemplated more than $18 billion of operating cash flow, approximately $2.5 billion of repurchases and a return toward 40% debt-to-capital. Q1 delivered $8.9 billion of operating cash flow, reduced leverage to 42.9% and accelerated at least $2 billion of buybacks into the first half. Because that amount was pulled forward rather than added to the annual plan, completion is expected. The incremental signal is whether UNH raises the full-year repurchase outlook while continuing to delever.

The strongest update would show that both a higher EPS floor and additional capital return are funded by a stronger operating and cash-flow base.

2Q Outcome Framework

Headline EPS alone will not determine the quality of the print. The key variables are Q1 claims completion, current medical cost trend, the June reserve position and the credibility of the second-half segment and guidance cadence.

Exhibit 4. UNH 2Q26 Outcome Framework

My modeled outcome is a clean print: Q1 claims complete favorably, producing an MCR approximately 15 basis points better than consensus; underlying utilization remains elevated but within 2026 pricing; UHC margin recovery stays on track; Optum Health is clean despite the expected sequential decline; and guidance is raised or meaningfully de-risked. Favorable prior-period development is part of the positive read-through, provided UNH also preserves a prudent June reserve position.

A mixed print would deliver an acceptable headline MCR but leave current-period trend, ending reserve quality or the second-half Optum cadence less clear. The recovery would remain intact, but the quarter would do little to advance the trust rebuild.

A weak print would show adverse current-year development, renewed utilization acceleration or a narrowing UHC pricing cushion. Any need to defend guidance through reserve releases or unrelated offsets would reopen the 2025 credibility concerns.

A clean print is my fundamental base case. It is not necessarily a call for an outsized positive share-price reaction: after the rerating since Q1, validation is increasingly reflected in the stock and the hurdle for incremental upside is materially higher.

Conclusion: The First Real Test

Q1 established that the recovery could be real; Q2 must show that it is durable. My base case is a clean print: favorable Q1 claims completion, elevated but controlled current trend, continued UHC margin repair, Optum performance consistent with the planned cadence and a higher or meaningfully de-risked full-year outlook.

The standard is higher than a consensus beat. Reserve development is valuable only if underlying trend and the June reserve position remain sound, while a guidance raise matters most when supported by operating performance rather than taxes, reserve releases or buybacks. Given the stock’s rerating, a clean result may validate the recovery without driving another outsized reaction, but it would materially strengthen the 2026 earnings base ahead of a fuller company view after the quarter.

Graver Research exists to bring the discipline of professional equity research to a broader and more accessible format.

The goal is to apply the same core habits that make institutional research valuable — clear coverage universes, explicit debates, evidence-based company analysis, industry context, earnings and policy read-throughs, and a disciplined focus on what can change the narrative — while publishing in a format that is useful to both investors and healthcare services professionals.

Traditional equity research is often written for institutional clients and distributed through enterprise relationships, banking platforms, and sales channels that most serious readers cannot access regardless of interest or willingness to pay. Graver Research is built around a different model: independent, sector-focused research that is more accessible, more flexible in format, and designed for readers who want to understand how healthcare services companies, policy, reimbursement, utilization, and market expectations fit together.

Some of the topics, terms, and business models in healthcare services are complex and highly specific. The core product is written for industry and healthcare investment professionals, but Graver Research will also publish primers and explainers for readers who are newer to the space or want a clearer foundation.

Subscribe now

Why this map exists

This “Healthcare Services Coverage Map” note is intended to be both the initial launching point for Graver Research and serve as a key regularly updated reference piece for subscribers. The map defines the Graver Research coverage universe and what subscribers should expect to receive on an ongoing basis. It also outlines the key company and subsector debates, and creates a baseline for future updates as earnings, policy developments, industry data, and market narratives change.

This piece does not serve as a full initiation or valuation framework for the coverage universe. Going forward, Graver Research will publish a mix of company notes, sector signals, policy and regulatory read-throughs, data snapshots, earnings/event notes, and recurring coverage maps. The common thread will be the same: identify the debates that matter, connect company fundamentals to industry and policy context, and update the view as the facts change.

What “healthcare services” means

Healthcare services is often used as a catch-all label for the parts of the healthcare industry that are not biopharma, medical technology, or life sciences tools. Those categories are often centered on products: drugs, devices, diagnostics, equipment, or research inputs. Healthcare services is different. It is more about systems, infrastructure, payment flows, care delivery, distribution, administration, outsourcing, and execution.

That makes the category broad and sometimes imprecise. A managed care company, a hospital operator, a drug distributor, and a clinical research organization all sit in different parts of the healthcare value chain. They have different customers, margin structures, regulatory exposures, capital intensity, and earnings drivers. But they share a common feature: each helps determine how healthcare is financed, accessed, delivered, administered, or supported.

In that sense, healthcare services is the operating layer of the healthcare system. It includes the companies that insure members, manage medical cost risk, contract with providers, deliver care, distribute drugs, process claims, run networks, support clinical development, manage data, and help large healthcare organizations function. The sector is where policy, reimbursement, utilization, labor, contracting, local market structure, and corporate execution show up most directly in public company fundamentals.

That is also what makes the sector difficult to analyze as one simple group. The key variables for a Medicare Advantage payer are not the same as the key variables for a hospital operator or pharmaceutical distributor. A utilization trend that pressures one subsector may benefit another. A reimbursement change may matter differently depending on payer mix, geography, customer concentration, or the ability to reprice risk. The same healthcare headline can therefore produce very different business implications across the group.

The initial coverage universe

Graver Research will begin with an initial coverage universe of 10 public companies that are among the most important for tracking the broader narratives, earnings debates, and policy implications across healthcare services.

This list is not meant to be exhaustive. The broader public healthcare services universe includes more than 100 companies across managed care, providers, distribution, services, technology, outsourcing, diagnostics, post-acute care, physician enablement, and adjacent areas. Graver Research will follow that broader universe where relevant, but the goal of the initial coverage list is to create a focused anchor group that can be covered consistently and thoughtfully.

The starting universe spans four major subsectors: managed care, hospitals, healthcare distribution, and CRO / outsourcing. These groups represent a large share of public healthcare services market capitalization and sit at the center of many of the sector’s most important current debates: medical cost trend, Medicare Advantage economics, Medicaid and ACA normalization, hospital volume and labor dynamics, specialty distribution growth, capital allocation, biopharma outsourcing demand, and the relationship between policy change and company-level earnings power.

Over time, this universe will likely broaden and evolve. Companies may be added as new debates become more important, or as adjacent subsectors deserve more dedicated coverage. For now, these 10 companies provide a practical starting point: large, liquid, strategically relevant businesses that together offer a useful lens into the state of healthcare services.

Exhibit 1 below provides a simple starting snapshot of the initial coverage universe: Market Capitalization, forward revenue, primary valuation, and recent total return performance.

Exhibit 1: Coverage Universe Snapshot

How the subsectors have traded

Healthcare services does not trade as one unified group. The divergence is clear in Exhibit 2 below, and it reflects a broader point about the sector: different subsectors can be exposed to the same underlying healthcare driver in very different ways.

Utilization is a simple example. Rising healthcare utilization can be positive for hospitals if it supports volumes, acuity, and operating leverage. It can be positive for distributors if it flows through prescription or specialty drug volumes. It can be negative for managed care companies if medical cost trend is underpriced or emerges faster than rates and benefit design can adjust. For CROs and outsourced services companies, near-term stock performance may have less to do with medical utilization and more to do with biopharma funding, backlog conversion, and customer spending cycles.

Even that framing is too static. These relationships can change over time depending on pricing, policy, contract structure, payer mix, market expectations, and the starting point for each stock. A driver that looks like a headwind in one period can become manageable if it is repriced. A favorable end-market trend can still disappoint if expectations were too high. As with any public company, the market reaction is rarely just about the direction of the driver; it is about the driver relative to expectations.

That is why healthcare services needs to be analyzed by subsector and company-specific debate, not as a single monolithic category. Performance can diverge sharply across managed care, hospitals, distribution, and CRO / outsourcing. It can also vary meaningfully within a subsector. In managed care, for example, exposure to commercial risk, Medicare Advantage, Medicaid, ACA marketplaces, PBMs, and care delivery assets can lead to very different earnings sensitivities and investor debates.

Exhibit 2 shows how the four initial subsectors covered by Graver Research have performed over the past three years. The baskets use a broader group of stocks than the initial 10-company coverage universe in order to better represent subsector-level performance. The constituents are listed in the caption below the chart.

Exhibit 2: 3-Year Indexed Total Return by Subsector

The key company debates

Each company in the initial coverage universe has a different setup. Some are working through utilization and reimbursement resets. Others are trying to prove the durability of specialty growth, PBM model changes, vertical integration, or biopharma demand recovery. Even within the same subsector, the stock debates can be very different.

Exhibit 3 below is meant to track the current narrative for each company. The goal is to identify the live debate, the evidence that could change investor perception, and the key variables that should matter most over the next several quarters.

Future company specific notes will go deeper on each of these debates, beginning with UNH.

Exhibit 3: Coverage Debate Tracker

The subsector setup

The initial coverage universe spans four broad subsectors: managed care, hospitals, distribution, and CRO / outsourcing. Each group sits in a different part of the healthcare services value chain, but each is exposed to the same broad question: how do changes in utilization, reimbursement, policy, market structure, and customer behavior flow through to company-level earnings power?

Managed Care

Managed Care is the largest and most complex debate. The group is working through overlapping resets in Medicare Advantage, Medicaid, ACA marketplaces, PBM transparency, commercial pricing, vertical integration, and public / regulatory scrutiny. The central question is whether 2025 and 2026 represent a painful but manageable reset, or whether normalized earnings power is structurally lower than investors previously assumed.

Medicare Advantage is the most visible pressure point. HUM is the purest test because its recovery depends heavily on Stars, benefit design, utilization, retention, and the ability to rebuild MA margins over the next several years. UNH and CVS also have meaningful MA exposure, but their debates extend into broader platforms and services. Medicaid and ACA add another layer. ELV and CNC are the clearest examples of companies trying to show that rate catch-up, cost management, repricing, and risk adjustment can restore margins after a period of elevated trend and morbidity pressure. CI provides the counterpoint: a more employer-focused and asset-light services driven model where the debate is less about government-program funding and more about PBM transition, commercial discipline, specialty pharmacy, and capital return.

Across the group, the most important question is whether managed care companies can still price, design benefits, manage cost, and adapt fast enough to protect long-term earnings power in a more difficult utilization and policy environment.

Hospitals

Hospitals have a different setup. Utilization is generally a positive driver when it supports admissions, acuity, operating leverage, and commercial revenue. HCA is the clearest hospital benchmark because it combines scale, strong local-market networks, disciplined capital allocation, outpatient expansion, and a long track record of cost control. The debate is not whether HCA is a high-quality operator. It is whether even a high-quality operator can fully absorb policy and payer-mix pressure.

ACA exchange attrition can reduce volumes, shift patients toward uninsured status, pressure collections, and change utilization patterns. Supplemental payments can offset some of that pressure, but they are variable and difficult to underwrite. Labor and hospital-based physician costs also remain important. The hospital setup is therefore a balance between attractive core demand and the reality that coverage, reimbursement, and payer mix can still materially influence reported earnings.

Distribution

Distribution is no longer just a low-margin drug logistics story. MCK and COR both show how scale distribution is becoming a foundation for specialty-enabled healthcare services. Specialty drug utilization, oncology innovation, GLP-1s, biosimilars, health-system services, provider relationships, biopharma services, workflow tools, and capital allocation are now central to the debate.

MCK represents the cleaner specialty-led compounder, with oncology, multispecialty, CoverMyMeds, biopharma access services, data, and portfolio simplification supporting the growth story. COR is making a more direct move into specialty physician infrastructure through OneOncology, Retina Consultants of America, and EyeSouth. The key question for both is whether specialty services can sustain premium earnings growth after a strong period of execution, or whether growth normalizes as GLP-1 revenue, biosimilars, customer shifts, list-price changes, and acquisition contribution mature.

CRO / Outsourcing

Contract Research Organizations and Outsourcing is centered on biopharma demand recovery and AI. IQV is the primary lens because it spans clinical development, commercial outsourcing, real-world data, analytics, and life-sciences technology. The first question is whether large pharma decision-making and biotech funding are improving enough to support sustained bookings, backlog conversion, and revenue growth. The second is whether AI is a threat or a moat.

IQV is arguing that useful AI in life sciences requires proprietary data, compliance, domain expertise, and embedded workflows. If that is right, AI can become a revenue and margin opportunity. If not, parts of CRO, analytics, and consulting work could face pricing or automation pressure. That makes IQVIA the cleanest test of whether CRO / outsourcing can reaccelerate after several years of uncertainty.

What Graver Research will track

The goal is to understand which developments actually matter for normalized earnings power, competitive position, and long-term business value.

That requires combining multiple inputs. Company filings, earnings calls, investor presentations, and quantitative company data are the starting point. Industry data helps supplement and test management commentary. Conversations with operators, investors, consultants, and others across the healthcare ecosystem can help assess whether the public narrative matches what is happening in the field. My decade of experience following healthcare services companies over multiple cycles provides the context for separating signal from noise.

The research framework will focus on the variables that most often drive healthcare services fundamentals.

Utilization is one of the most important. Changes in admissions, procedures, pharmacy volume, acuity, care intensity, and site of care can create very different implications across subsectors. Higher utilization may be positive for hospitals or distributors, negative for managed care if underpriced, and less directly relevant for CROs in the near term.

Reimbursement and rate cycles are equally important. Medicare Advantage rates, Medicaid rate updates, commercial pricing, supplemental payments, exchange pricing, and manufacturer / distributor economics often determine whether cost pressure can be absorbed or repriced. Policy and regulation matter because healthcare services business models are deeply connected to government programs, payment rules, risk adjustment, PBM scrutiny, prior authorization, transparency requirements, and coverage policy.

Membership and enrollment will also be central, especially in managed care. Growth is not automatically good if it comes with worse morbidity, weaker retention, underpriced risk, or unattractive lifetime value. Payer mix matters for providers because a volume trend can look very different depending on whether it is commercial, Medicare, Medicaid, exchange, or uninsured.

Labor and capacity remain critical for facility-based care and care delivery businesses. Wage inflation, contract labor, physician costs, throughput, staffing models, and capital investment can determine whether revenue growth converts into margin. Medical cost trend is the managed care equivalent: the key question is not just whether cost trend is high, but whether it is understood, priced, managed, and reflected in expectations.

Across all subsectors, Graver Research will track contracting power, capital allocation, earnings quality, and valuation.

The objective is to build a disciplined research process around the variables that matter. Not every headline changes the story. The work is to identify which facts actually change the debate.

How this map will evolve

This coverage map is meant to be a starting point, not a static document. Graver Research will update it periodically as company fundamentals, subsector narratives, policy developments, and market expectations change.

The likely cadence will be quarterly, but the map may be updated sooner if the facts change materially. In healthcare services, narratives can move quickly: a rate notice, reimbursement update, utilization inflection, policy proposal, acquisition, or management change can alter the debate before the next formal reporting cycle.

Future versions may add companies, refine the subsector groupings, change the key variables being tracked, or reframe the central debate for individual names.

The next piece will move from the map to company-level work, beginning with UNH. That note will go deeper on one of the most important current debates in healthcare services: whether UNH’s recent reset is the beginning of a recovery in normalized earnings power or evidence of a more durable impairment.